<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983775</url>
  </required_header>
  <id_info>
    <org_study_id>PKPD_SQ_1</org_study_id>
    <nct_id>NCT00983775</nct_id>
  </id_info>
  <brief_title>Pharmacology of Insulin Injected With Jet-Injection</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Profile of Rapid Acting Insulin Injected by Needle-free Jet-injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacological profile of insulin administered
      with jet-injection with that of insulin injected with a conventional insulin pen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(time to) maximal glucose infusion rate</measure>
    <time_frame>0-8 hours after insulin injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(time to) maximal insulin concentration</measure>
    <time_frame>0-8 hours after insulin injection</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>healthy low dose insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy high dose insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>jet injector (SQ pen/Novopen III)</intervention_name>
    <description>The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.</description>
    <arm_group_label>healthy low dose insulin</arm_group_label>
    <other_name>SQ pen</other_name>
    <other_name>Novopen III</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>jet injector (SQ pen/Novopen III)</intervention_name>
    <description>The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.</description>
    <arm_group_label>healthy high dose insulin</arm_group_label>
    <arm_group_label>type 1 diabetes mellitus</arm_group_label>
    <other_name>SQ pen</other_name>
    <other_name>Novopen III</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years

          -  Body-mass index 18-28 kg/m2

          -  Blood pressure &lt;160/90 mmHg

          -  Stable glycaemic control with HbA1c 6.5-9.0% (for patients with type 1 diabetes
             mellitus)

          -  Duration of diabetes &gt;1 year (for patients with type 1 diabetes mellitus)

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Chronic use of medication other than oral contraceptives or thyroid hormone
             replacement therapy (with stable euthyroidism for at least 3 months)

          -  Chronic use of medication other than insulin or low-dose angiotensin-converting enzyme
             (ACE) inhibitor or angiotensin receptor blocker (ARB) treatment (for patients with
             type 1 diabetes mellitus)

          -  Type 2 diabetes in first-degree relatives (for healthy subjects)

          -  History of a major cardiovascular disease event (myocardial infarction, stroke,
             symptomatic peripheral artery disease, coronary bypass surgery, percutaneous coronary
             or peripheral artery angioplasty)

          -  Pregnancy

          -  Macroalbuminuria, i.e. urinary albumin excretion &gt;200 microg/min in collected urine
             sample or urinary albumin-to-creatinine ratio &gt;300 mg/g in spot urine sample (for
             patients with type 1 diabetes mellitus)

          -  Symptomatic diabetic neuropathy (for patients with type 1 diabetes mellitus)

          -  Proliferative diabetic retinopathy (a history of proliferative retinopathy that was
             successfully treated with laser coagulopathy is not an exclusion criterion) (for
             patients with type 1 diabetes mellitus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees J Tack, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>P.O. Box 9101</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cees Tack, MD PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>Pharmacokinetic profile</keyword>
  <keyword>Pharmacodynamic profile</keyword>
  <keyword>insulin</keyword>
  <keyword>jet injector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

